抗PD-1治療後のメラノーマ患者におけるRP1とニボルマブの治療は期待できる結果を示した. Replimune's trial shows promising results for RP1 and nivolumab in melanoma patients post anti-PD-1.
Replimune Groupは,SITC 2024でのIGNYTE臨床試験の結果をシェアし,以前抗PD-1治療に失敗したメラノーマ患者でRP1とニボルマブの組み合わせを試験した. Replimune Group shared findings from its IGNYTE clinical trial at the SITC 2024, testing the combination of RP1 and nivolumab in melanoma patients who previously failed anti-PD-1 therapy. この裁判は,全反応率33.6%を表明し,中央反応期間は2,6ヶ月である. The trial showed a 33.6% overall response rate, with a median response duration of 21.6 months. レスポンサーの病変は大幅に減少し,初期のバイオマーカーデータでは,強い免疫反応が示された. Most lesions in responders decreased in size significantly, and initial biomarker data indicated a strong immune response. 1年後の生存率は75.3%で注目されました. Survival rates were notable, with 75.3% at one year.